SCHEMBL5137586

SCHEMBL5137586

CCCCN(Cc1cc(F)ccc1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
HDAC1 Q13547 1/20 0.38
P2RX7 Q99572 1/20 0.37
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 6/20 0.36
CYP3A4 P08684 6/20 0.36
HPGD P15428 6/20 0.36
HSD17B10 Q99714 6/20 0.36
TSHR P16473 6/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CRHR1 P34998 2/20 0.36
DRD2 P14416 2/20 0.35
DRD1 P21728 2/20 0.35
DRD4 P21917 2/20 0.35
HTR2C P28335 2/20 0.35
DRD3 P35462 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134844 0.96 C5AR1 (0.44) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5137131 0.95 C5AR1 (0.41) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5136102 0.93 C5AR1 (0.39) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5135016 0.92 C5AR1 (0.41) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5137572 0.91 C5AR1 (0.39) C5AR1HDAC1KDM4EALDH1A1CYP3A4
SCHEMBL5071864 0.90 P2RX7 (0.43) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5135670 0.89 C5AR1 (0.43) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5137427 0.89 GNRHR (0.41) C5AR1HDAC1KDM4EALDH1A1HSD17B10
SCHEMBL5136224 0.89 C5AR1 (0.41) C5AR1HDAC1P2RX7KDM4EALDH1A1
SCHEMBL5135688 0.87 C5AR1 (0.45) C5AR1P2RX7KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed